Evaluation of therapeutic effects of spironolactone on schistosomal pulmonary arterial hypertension by echocardiography
- VernacularTitle:应用超声心动图观察螺内酯对血吸虫性肺动脉高压的疗效
- Author:
Daoming ZONG
;
Xiaogong ZHAO
;
Weicheng DENG
;
Sixi CHEN
;
Keying SUN
;
Yuesheng LI
- Publication Type:Journal Article
- Keywords:
Schistosomal pulmonary arterial hypertension(SPAH);
Mean pulmonary arterial pressure (mPAP);
Pulmonary arterial diameter(PAD);
6-minute walking test(6-MWT);
Spironolactone;
Echocardiography
- From:
Chinese Journal of Schistosomiasis Control
2006;18(3):207-210
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the therapeutic effect of spironolactone on schistosomal pulmonary arterial hypertension(SPAH). Methods A total of 62 patients suffered from hepatosplenic schistosomiasis with pulmonary arterial hypertension were divided into the spironolactone group(n=31) and control group (n=31). All the patients underwent serial echocardiography and the clinical effect before and after the treatment was evaluated by assessing the mean pulmonary arterial pressure (mPAP) and pulmonary arterial diameter (PAD). At the same time, the varieties of the clinical symptoms, signs and the distance of the 6-minute walking test (6-MWT) were investigated. Results In spironolactone group, mPAP(-x±s) decreased from (31.8±7.1) mmHg to (21.2±2.1) mmHg, PAD(-x±s) decreased from (28.0±5.0) mm to (20.0±3.5) mm before and after the treatment respectively(P<0.01). There were significant differences in mPAP, PAD, the distance of 6-MWT and the heart function before and after the treatment in the spironolactone group. However, the data did not show the significant difference in the control group. Conclusion The therapeutic effect of spironolactone in the treatment of SPAH is satisfactory.
